Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24109229 | 1.00 | DPP4 (0.32) | DPP4DPP7KDM4EPARP1 | |
| SCHEMBL22675342 | 1.00 | DPP4 (0.32) | DPP4DPP7KDM4EPARP1 | |
| SCHEMBL5027448 | 0.93 | — | — | |
| SCHEMBL24109224 | 0.93 | — | — | |
| SCHEMBL11223836 | 0.82 | — | — | |
| SCHEMBL25781324 | 0.77 | TP53 (0.31) | — | |
| SCHEMBL29296260 | 0.74 | CA1 (0.33) | — | |
| SCHEMBL6903141 | 0.73 | KDM4E (0.42) | KDM4E | |
| SCHEMBL681878 | 0.73 | KDM4E (0.42) | KDM4E | |
| SCHEMBL89043 | 0.73 | KDM4E (0.42) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230183168-A1 | IONIZABLE LIPIDS AND COMPOSITIONS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| WO-2022257833-A1 | INTERMEDIATE OF SUBSTITUTED PHENYLPROPYL PYRIDINE DERIVATIVE AND PREPARATION METHOD FOR INTERMEDIATE | 上海海雁医药科技有限公司 | 2022-12-15 | — | — | WO | disclosed |
| US-20210386721-A1 | SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2021-12-16 | — | — | US | disclosed |
| WO-2020228649-A1 | SUBSTITUTED PHENYLPROPENYLPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| EP-3397616-B1 | LSD1 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-10633345-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10208021-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180201603-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-07-19 | — | — | US | disclosed |
| US-20110160188-A1 | PARAMYXOVIRUS FAMILY INHIBITORS AND METHODS OF USE THEREOF | EMORY UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
| US-20090258902-A1 | BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS | CONCERT PHARMACEUTICALS INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-7514068-B2 | Biphenyl-pyrazolecarboxamide compounds | CONCERT PHARMACEUTICALS INC. (US) | 2009-04-07 | — | — | US | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20070276001-A1 | Biphenyl-pyrazolecarboxamide compounds | CONCERT PHARMACEUTICALS INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070066657-A1 | obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist | CONCERT PHARMACEUTICALS INC. (US) | 2007-03-22 | — | — | US | disclosed |
| CN-1481377-A | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteinases and TNF-alpha | ����˹�ж�-����˹˹����ҩƷ��˾ | 2004-03-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183168-A1 | IONIZABLE LIPIDS AND COMPOSITIONS AND USES THEREOF | SLC10A1, PYGL, FABP1 | DPP4 2937/4885DPP7 3541/4885KDM4E 4861/4885 |
| US-20110160188-A1 | PARAMYXOVIRUS FAMILY INHIBITORS AND METHODS OF USE THEREOF | MAVS, SARS1, CDV3 | DPP4 1504/4885DPP7 1329/4885KDM4E 984/4885 |
| US-20090258902-A1 | BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS | CNR2, CNR1, GPR119 | DPP4 643/4885DPP7 1082/4885KDM4E 706/4885 |
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | DPP4 620/4885DPP7 905/4885KDM4E 1604/4885 |
| US-10208021-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | TFPI, TFPI2, KLKB1 | DPP4 900/4885DPP7 922/4885KDM4E 492/4885 |
| US-20210386721-A1 | SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS | PDCD1, CD274, PDCD1LG2 | DPP4 52/4885DPP7 104/4885KDM4E 412/4885 |
| US-20180201603-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | DPP4 900/4885DPP7 922/4885KDM4E 492/4885 |
| US-10633345-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | DPP4 620/4885DPP7 391/4885KDM4E 1757/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | DPP4 2163/4885DPP7 1630/4885KDM4E 1060/4885 |
| US-20070276001-A1 | Biphenyl-pyrazolecarboxamide compounds | CNR2, CNR1, GPR119 | DPP4 643/4885DPP7 1082/4885KDM4E 706/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DPP4 308/4885DPP7 221/4885KDM4E 190/4885 |
| US-20070066657-A1 | obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist | CNR2, CNR1, GPR119 | DPP4 455/4885DPP7 1039/4885KDM4E 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.